This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Monk, B. J. Articles by Koh, W.-J. Search for Related Content PubMed PubMed Citation Articles by Monk, B. J. Articles by Koh, W.-J.

Multimodality Therapy for Locally Advanced Cervical Carcinoma: State of the Art and Future Directions

Bradley J. Monk, Krishnansu S. Tewari, Wui-Jin Koh

From the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California-Irvine Medical Center, Orange, CA; and the Department of Radiation Oncology, Fred Hutchinson Cancer Research, University of Washington, Seattle, WA

Address reprint requests to Bradley J. Monk, MD, FACS, FACOG, Division of Gynecologic Oncology, Department of Obstetrics/Gynecology, Chao Family Comprehensive Cancer Center, University of California-Irvine Medical Center, Building 56, Rm 262, 101 The City Dr, Orange, CA 92868; e-mail: bjmonk{at}uci.edu

Globally, cervical cancer is the second most common cause of cancer-related mortality among women causing approximately 234,000 deaths annually among developing countries and killing 40,000 in developed nations. Most of these deaths occur in women with bulky or locally advanced cervical cancer, International Federation of Gynecology and Obstetrics (FIGO) stages IIB through IVA, when lesions are not amenable to high cure rates with surgery or radiation (RT). The standard prescription for RT used to treat locally advanced cervical cancer has been dictated by common practice and patterns of care studies. In contrast, the addition of concomitant chemotherapy to RT has been studied in a number of randomized prospective trials, which are discussed in detail. When added to RT, cisplatin reduces the relative risk of death from cervical carcinoma by approximately 50% by decreasing local/pelvic failure and distant metastases. In 1999, weekly intravenous cisplatin at 40 mg/m² for 6 weeks in combination with RT was established as a new standard for the treatment of locally advanced cervical carcinoma. More recently, this recommendation has been expanded to include women with FIGO stage IB2 lesions as well as those with bulky stage IIA cancers. This monograph reviews the state of the art in treating locally advanced cervical cancer with combined chemotherapy and RT and discusses clinical and pathologic prognostic factors that impact cure. Quality of life during and after multimodality therapy is considered as well as ongoing clinical trials and future directions.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				S. A. Cannistra and W. P. McGuire Progress in the Management of Gynecologic Cancer J. Clin. Oncol., July 10, 2007; 25(20): 2865 - 2866. [Full Text] [PDF]